Journal
BIOMATERIALS
Volume 33, Issue 28, Pages 6739-6747Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.biomaterials.2012.06.008
Keywords
Nanoparticles; Targeted delivery; Breast cancer; Tumor imaging; Tumor therapy
Funding
- National Natural Science Foundation of China [81101738, 81172078]
- National 973 Basic Research Program of China [2010CB529902]
- Nano-Science and Technology from Science and Technology Commission of Shanghai Municipality [1052nm 05900]
- Medical-Engineering Joint Funds from the Shanghai Jiao Tong University [YG2011MS53]
- Scientific Project of Shanghai Municipal Health Bureau [20114168]
Ask authors/readers for more resources
Cyclic peptide (arginine-glycine-aspartic-glutamic-valine acid, cRGD)-modified monomethoxy (polyethylene glycol)-poly (D,L-lactide-co-glycolide)-poly (L-lysine) nanoparticles (mPEG-PLGA-PLL-cRGD NPs) with antitumor drug Mitoxantrone (DHAQ) or fluorescence agent Rhodamine B (Rb) encapsulated in their interior were prepared. The remarkable features of the mPEG-PLGA-PLL-cRGD NPs are the effective improvement for the cytotoxicity and uptake of the cell in vitro, and the significant enhancement of delivery ability for DHAQor Rb in vivo. As a consequence, an excellent therapeutic efficiency for cancer is obtained, demonstrating the mPEG-PLGA-PLL-cRGD NPs play a key role in enhancing cancer therapeutic efficiency. Crown Copyright (C) 2012 Published by Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available